Mesenchymal stromal cells in kidney transplantation

Federica Casiraghi; Giuseppe Remuzzi

doi:10.1097/mnh.0000000000000461

Abstract

1 min read

Many issues should be addressed before MSC-based therapy becomes a standard treatment protocol for kidney transplantation. A better understanding of the MSC mechanism of action and the identification of biomarkers of response to therapy will inform the rational design of the most effective clinical protocol and the selection of patients amenable to safe immunosuppressive drug withdrawal.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2019

Mesenchymal Stromal Cells for Transplant Tolerance

Manuel Alfredo Podestà, Giuseppe Remuzzi, Federica Casiraghi

Article2013

Mesenchymal stromal cells to promote kidney transplantation tolerance

Federica Casiraghi, Giuseppe Remuzzi, Norberto Perico

Article2019

Mesenchymal stromal cell-based therapy in kidney diseases and transplantation

Federica Casiraghi, Giuseppe Remuzzi

Article2013

Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation

Norberto Perico, Federica Casiraghi, Eliana Gotti, Martino Introna, Marta Todeschini, Regiane Aparecida Cavinato, Chiara Capelli, Alessandro Rambaldi, Paola Cassis, Paola Rizzo, Monica Cortinovis, Marina Noris, Giuseppe Remuzzi

Article2012

Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation

Federica Casiraghi, Nadia Azzollini, Marta Todeschini, Regiane Aparecida Cavinato, Paola Cassis, Samantha Solini, Cinzia Rota, Marina Morigi, Martino Introna, Ramona Maranta, Norberto Perico, Giuseppe Remuzzi, Marina Noris